

Rua Bioscience Limited

Results announcement

Results for announcement to the market		
Name of issuer	Rua Bioscience Limited	
Reporting Period	6 months to 31 December 2023	
Previous Reporting Period	6 months to 31 December 2022	
Currency	NZD	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$141	(44%)
Total Revenue	\$141	(44%)
Net profit/(loss) from continuing operations	-\$10,851	(1,610%)
Total net profit/(loss)	-\$10,851	(1,610%)
Interim/Final Dividend		
Amount per Quoted Equity Security	\$0.00	
Imputed amount per Quoted Equity Security	\$0.00	
Record Date	\$0.00	
Dividend Payment Date	\$0.00	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.05	\$0.07
A brief explanation of any of the figures above necessary to enable the figures to be understood	Refer unaudited interim financial statements	
Authority for this announcement		
Name of person authorised to make this announcement	Paul Naske	
Contact person for this announcement	Paul Naske	
Contact phone number	+64 (21) 445 154	
Contact email address	Paul.naske@ruabio.com	
Date of release through MAP	29 February 2024	

Unaudited financial statements accompany this announcement.